AKT1 and neoplasm: Further, knockdown of Akt or the AS160 ortholog Plx in byn > RAP tumours strongly reduced both glucuronidation pathway activity—based on decreased levels of released UDP—and resistance to trametinib (Figs. 1a and 3f–i).